Comparison of Single and Combined Treatment with Exenatide and Metformin on Menstrual Cyclicity in Overweight Women with Polycystic Ovary Syndrome

• DOI: 10.1210/jc.2008-0115
• Publication Date: 2008-05-07T03:02:00Z
• Authors: Karen Elkind-Hirsch; Ory Marrioneaux; Madhu Bhushan; Denise Vernor; Rajat Bhushan
• Keywords: Free androgen index

Abstract Context: Insulin resistance and obesity are common features of the polycystic ovary syndrome (PCOS). Weight loss use insulin-lowering drugs have been shown to improve both reproductive metabolic aspects PCOS. Objective: We evaluated exenatide (EX) metformin (MET), alone in combination (COM), on menstrual cyclicity, hormonal parameters, profiles, inflammatory markers overweight, insulin-resistant women with Design, Setting, Participants: Sixty overweight oligoovulatory PCOS (body mass index > 27; 18–40 yr) were randomized one three treatment groups: MET [1000 mg twice daily (BID)], EX (10 μg BID), or COM (MET 1000 BID, 10 BID) for 24 wk. The primary outcome was frequency; secondary measures included changes ovulation rate, insulin action, anthropometric measures, androgen levels, markers. Results: Forty-two (70%) patients completed study. therapy superior monotherapy improving free index, sensitivity reducing weight abdominal fat. Both arms more effective promoting than (P = 0.003). Conclusions: appears better either cycle frequency derangements. A marked decrease central adiposity could partly explain improvements function, insulin-glucose adiponectin observed these treated therapy. Larger trials longer duration warranted assess long-term efficacy safety combined EX-MET